Nautilus (NAUT) General Counsel Reports 20,000-Share Purchase
Rhea-AI Filing Summary
Matthew B. Murphy, listed as General Counsel and Trustee of the Murphy Family Trust, reported transactions in Nautilus Biotechnology, Inc. (NAUT) on 09/04/2025.
He purchased 20,000 shares of Nautilus common stock at $0.6429 per share and disposed of 1,250 shares on the same transaction date. After the reported purchase, the filing shows beneficial ownership of 74,140 shares held indirectly through the Murphy Family Trust.
Positive
- Insider purchase disclosed of 20,000 shares at $0.6429, increasing reported indirect holdings to 74,140 shares
- Timely filing and signature (transaction dated 09/04/2025, signed 09/05/2025) demonstrating compliance with Section 16 reporting
Negative
- Small disposal of 1,250 shares was also reported, partially offsetting purchased shares
Insights
TL;DR: Insider purchased a modest number of shares; net indirect holdings increased to 74,140 shares.
From a trading perspective, the acquisition of 20,000 shares at $0.6429 is a modest insider buy and increases the reporting persons indirect stake held in the Murphy Family Trust to 74,140 shares. The disposal of 1,250 shares partially offsets the purchase but is small relative to the acquired amount. These transactions are routine disclosures under Section 16 and do not, by themselves, convey material corporate events.
TL;DR: Transaction is clearly disclosed; trustee status and officer role are noted, supporting governance transparency.
The filing identifies Matthew B. Murphy as both an officer (General Counsel) and the Trustee of the Murphy Family Trust, which holds the indirectly owned shares. The Form 4 properly reports both acquisition and disposition activity on 09/04/2025 and includes a signature dated 09/05/2025. This disclosure aligns with Section 16 requirements and supports timely insider reporting practices.